PINGUIN
Type 2 diabetes is a serious condition that results from defects in insulin secretion and insulin action. Women with a history of gestational diabetes (GDM), in particular women requiring insulin therapy to control hyperglycaemia during GDM, are at increased risk to develop type 2 diabetes postpartum. There are no approved therapies that prevent development of type 2 diabetes in women with recent GDM. Vildagliptin is a highly selective and reversible inhibitor of dipeptidyl peptidase IV, the enzyme responsible for the degradation and inactivation of the incretin hormones GLP-1 and GIP.
PINGUIN (Postpartum Intervention in Women with Gestational Diabetes using Insulin) is a randomized double-blind placebo controlled and investigator-initiated trial to determine the efficacy of 24 month 50 mg b.i.d. Vildagliptin treatment to reduce progression to diabetes in islet autoantibody negative women with recent insulin treated GDM. As concomitant treatment, all subjects will receive standard lifestyle recommendations. The primary outcome is diabetes diagnosed on the basis of a six-monthly oral glucose tolerance test according to 1997 ADA criteria and 47 of 140 women have been included. The trial contributes to the development of preventive therapies in young women at high risk for diabetes.
Participants: Women who are > 18 years of age, less than 9 months postpartum, and who had insulin treated GDM during their most recent pregnancy.
Further information: www.pinguin-studie.de
Contact person: Dr. med. Anna Huppert
Phone: +49-(0)89 / 3187 - 4796
Email: pinguin@lrz.uni-muenchen.de